Navigation Links
ARMGO Pharma Receives Research Grant Award from Kennedy's Disease Association to Support Advancement of Rycal Compounds

TARRYTOWN, N.Y. and COARSEGOLD, Calif., Nov. 6, 2013 /PRNewswire/ -- ARMGO Pharma and the Kennedy's Disease Association (KDA) today announced that a research grant has been awarded to support preclinical work on novel, orally available compounds that have potential as a novel treatment for Kennedy's Disease (also known as Spinal Bulbar Muscular Atrophy or SBMA). The project being advanced by ARMGO Pharma is focused on a novel class of small molecule drugs known as Rycals® which target the Ryanodine Receptor (RyR), an intracellular calcium channel that becomes leaky in disease states, including Kennedy's Disease, and contributes to loss of muscle strength and function.

Kennedy's Disease (KD) is a rare and currently incurable and non-treatable recessive X-linked, genetic progressive neuromuscular disease. Spinal and bulbar motor neurons are primarily affected causing muscle weakness and wasting (atrophy) throughout the body including the extremities (legs/arms) as well as in the face and throat. This results in speech and swallowing difficulties as well as major motor deficiencies. Kennedy's Disease is an adult-onset disease with symptoms usually appearing between the ages of 30 and 50.  It is estimated that 1 in 40,000 male individuals worldwide have the disease; however many go undiagnosed or misdiagnosed for years. The most frequent misdiagnosis is the fatal Lou Gehrig's Disease (ALS).

The focus of the research project is to assess the therapeutic effects of orally bioavailable, small molecule modulators of the RyR (known as Rycals) which repair pathophysiologic calcium leak in skeletal muscle disease to reverse chronic muscle weakness. Given recent evidence that Kennedy's Disease may affect muscles directly, causing them to become weak independent of the nervous system, such modulators have the potential to improve motor function in patients affected by KD (SBMA).  Rycals restore normal RyR function, improve skeletal muscle biochemical markers and improve function of pathologic muscle in various preclinical models of skeletal muscle disease. Recent evidence from a mouse model of KD suggests that toxic androgen receptor may cause muscle weakness by impairing the function of RyR, resulting in an elevated concentration of cytosolic calcium and the loss of muscle strength in KD affected men.

"We are very pleased to have been selected by the KDA to receive funding which will support the advancement of our scientific platform against Kennedy's Disease, complementing our lead Rycal programs for heart failure and Duchenne Muscular Dystrophy," said Dr. Sapan Shah, President and CEO of ARMGO Pharma. "We are excited at the possibility to expand our Rycal research and development program into skeletal muscle diseases, such as Kennedy's Disease, where new treatment options for patients are desperately needed," remarked Dr. Michael Blanar, Chief Scientific Officer of ARMGO Pharma and Principal Investigator of the KDA-funded research project.

Upon granting the award, the Kennedy's Disease Association commented, "The KDA is pleased to be able to partner with ARMGO, as part of our overall effort to cure KD.  Their proposal was highly ranked by our scientific reviewers and we are hopeful that this unique approach to combatting KD will lead to a treatment in the near future."

About ARMGO Pharma: ARMGO Pharma, Inc., is a privately held biopharmaceutical company dedicated to applying original, targeted science to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, musculoskeletal, and neurological disorders. The company's proprietary drugs, known as Rycals®, are a new class of oral agents that repair calcium leak through the ryanodine receptor calcium-release channel (RyR), which is located on the sarcoplasmic/endoplasmic reticulum of the cell. ARMGO Pharma has been awarded an exclusive, worldwide license from Columbia University for its RyR technology.

About the Kennedy's Disease Association:  The Kennedy's Disease Association is an all-volunteer organization, with 91¢ of every dollar funding Kennedy's Disease Research Grants and education. The Mission of the Kennedy's Disease Association is to:

  1. Financially support and promote medical research to find a cure for Kennedy's Disease
  2. Share information about Kennedy's Disease for those who seek it
  3. Improve awareness of Kennedy's Disease in the medical community
  4. Create a support system for those living with Kennedy's Disease
  5. Increase public awareness about Kennedy's Disease and its effects on families

Kennedy's Disease Association, P.O. Box 1105, Coarsegold, CA 93614-1105


http://www.kennedysdisease.orgContact: Dr. Sapan Shah

John A. Coakley, Sr. CEO, ARMGO Pharma

KDA Vice President (914) 425-0000

(443) 340-1111 

SOURCE ARMGO Pharma; Kennedy's Disease Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ARMGO Pharma Receives $1 Million Award from MDA to Support Advancement of Rycal Compound ARM210 as a Novel Treatment for Duchenne Muscular Dystrophy
2. Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
3. AcelRx Pharmaceuticals Reports Third Quarter 2013 Financial Results
4. Cumberland Pharmaceuticals Reports Third Quarter Financial Results
5. Jazz Pharmaceuticals Announces Third Quarter 2013 Financial Results
6. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
7. Aquavit Pharmaceuticals Adds New Advanced Drug Delivery Technology to Product Portfolio
8. KV Pharmaceutical Company Completes New Board with Appointment of Former Johnson & Johnson Executive
9. PDL BioPharma to Provide up to $50 Million Financing to Direct Flow Medical
10. Endo to Acquire Specialty Pharmaceutical Company Paladin Labs
11. New MTHFR Gene Test Extends Holistic Pharmacogenomics Approach to Treating Depression
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015   VolitionRx Limited (NYSE MKT: ... tests for a broad range of cancer types and other ... Micro Conference, which will be held December 1 - 3 in ... VolitionRx will be David Kratochvil , Chief Financial Officer ... Investor Relations. ® blood-based tests for colorectal ...
(Date:11/30/2015)... , November 30, 2015 PFE ... at up to 10 G protein-coupled receptor (GPCR) targets ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> Heptares Therapeutics ("Heptares"), ... and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE ...
(Date:11/30/2015)... and REHOVOT, Israel , ... specialty pharmaceutical company focused on acquiring and developing innovative ... announced the appointment of Keith A. Katkin ... Gregory J. Flesher , chief executive officer for ... building successful organizations.  As chairman, he will be able ...
Breaking Medicine Technology:
(Date:11/30/2015)... DC (PRWEB) , ... November ... ... Inc. (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: ... lessons learned from three innovative value-based care arrangements: Essentia Health and UCare, ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in the ... Matrix is a long-term resorbable surgical mesh intended to support and reinforce soft ...
(Date:11/30/2015)... Puerto Rico (PRWEB) , ... November 30, 2015 , ... ... active part of the San Juan Beauty Show held on November 8th and 9th ... was attended by media personalities, hair artists, renowned beauticians and top of the line ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... are pleased to announce their strategic partnership at the Radiological Society of ... Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation ...
(Date:11/30/2015)... ... 30, 2015 , ... World Patent Marketing , a ... household invention that provides an economical and easy way of gaining customized curtains. ... at 2.6%," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
Breaking Medicine News(10 mins):